Multiple sclerosis (MS) is a CNS disorder characterized by inflammation, demyelination and
neurodegeneration, and is the most common cause of acquired nontraumatic neurological …

Objective: Although regulatory authorities evaluate the risks and benefits of any new drug
therapy during the new drug‐approval process, quantitative risk–benefit assessment (RBA) …

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system
(CNS) in which inflammation, demyelination, and axonal loss occurs from the very early …

Modern neuropsychopharmacology commenced in the 1950s with the serendipitous
discovery of first-generation antipsychotics and antidepressants which were therapeutically …

While interest in the application of machine learning to improve healthcare has grown
tremendously in recent years, a number of barriers prevent deployment in medical practice …

The current process of benefit–risk assessment of medicines relies primarily on intuitive
expert judgment. Frameworks are needed for transparent, rational and defensible decision …

Decisions regarding the development, regulation, sale, and utilization of pharmaceutical and
medical interventions require an evaluation of the balance between benefits and risks. Such …

Drugs are approved by regulatory agencies on the basis of their assessment of whether the
available evidence indicates that the benefits of the drug outweigh its risks. In recent years …

Purpose Pharmaceutical formulation and treatment process attributes, such as dose
frequency and route of administration, can have an impact on quality of life, treatment …

Background Patient engagement is vital in multiple sclerosis (MS) in order to optimise
outcomes for patients, society and healthcare systems. It is essential to involve all …